Andrew Biankin

Andrew Biankin has a diverse and extensive work experience in the field of cancer research and precision medicine. Andrew began their career at the University of Glasgow in 2013, where they served as the Regius Professor of Surgery and Director of the Wolfson Wohl Cancer Research Centre. Andrew also held the role of Director of the Glasgow Precision Oncology Laboratory starting from January 2016.

In 2017, Biankin became the Executive Director of ICGC ARGO, a research consortium focused on advancing cancer genomics. During this time, they also worked as a Clinician Scientist at Cancer Research UK, contributing to the development of innovative cancer treatments.

Biankin's contributions to the field have been recognized by prestigious organizations. Andrew became a Fellow of the Academy of Medical Sciences in June 2017 and was also recognized as a Fellow of the Royal Society of Edinburgh in September 2015.

Additionally, Biankin has played a critical role in the establishment and leadership of various initiatives. Andrew chaired Precision-Panc, a precision medicine platform for pancreatic cancer, since January 2015. Andrew was also the Co-Lead of the Scottish Genomes Partnership at The Scottish Government from February 2016 to August 2021.

In recent years, Biankin has continued to make significant contributions to the field. In 2020, they founded Gabriel Precision Oncology and serves as its Director. Andrew is also the Chairperson of the Scientific Advisory Board at Cambridge Cancer Genomics since January 2020.

Overall, Andrew Biankin's work experience reflects their expertise in cancer research, precision medicine, and leadership in various research and clinical settings.

Andrew Biankin completed their education in a chronological order. Andrew first attended UNSW from 1985 to 1991, where they obtained a B.Med.Sc. and M.B., B.S. in the field of Medicine. Andrew then pursued further education at the Royal Australasian College of Surgeons from 1995 to 1998, earning a degree in Surgery (F.R.A.C.S.). Andrew went on to obtain a Doctor of Philosophy (Ph.D.) in Oncology and Cancer Biology from the Garvan Institute of Medical Research, although the specific start and end years are not provided. Finally, they undertook a Postdoctoral Fellowship in Oncology and Cancer Biology at The Johns Hopkins University from 2003 to 2005.